Cerebellar rTMS Theta Burst for Dual-task Walking in Parkinson's Disease

NCT ID: NCT04238000

Last Updated: 2020-01-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-01

Study Completion Date

2020-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objective of the study:

To test the efficacy of theta burst cerebellar stimulation on dual task walking in Parkinson's disease using a cross-over design and wearing sensors technology

Design:

Twenty Parkinson's disease patients with no dementia will be recruited for a cross-over sham-controlled study. Each patient will undergo a sham stimulation or a single session of cerebellar theta burst stimulation with a wash out period of at least 14 days.

Each patient will be evaluated before and after stimulation by a battery of gait and movement tests using wearing sensors technology .

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There are no medical effective treatments for dual-task gait in Parkinson's disease. Imaging, neurophysiology and pathology studies suggested cerebellum as possible target of brain stimulation for dual-task walking for theta Burst repetitive Transcranial magnetic stimulation

Objective of the study:

To test the efficacy of theta burst cerebellar stimulation on gait in Parkinson's disease using a cross-over design and wearing sensors technology

Design:

Parkinson's disease patients able to walk and without dementia/behavioral disturbances will be recruited for a cross-over sham-controlled study. Each patient will undergo a sham stimulation or a single session of cerebellar theta burst stimulation with a wash out period of at least 14 days.

Repetitive cerebellar theta burst stimulation will be performed by Duo-Mag XT100, using a 3 pulses at 50-Hz repeated at a rate of 5-Hz; 20 trains of 10 bursts given with 8-s intervals for a total of 600 pulses. Intensity of rTMS was set at the 80% of Amplitude of Motor Threshold (RMT) obtained in the left motor cortex for each subject.

A sample size of 20 subjects with complete stimulation (2 stimulations per subject, for a total number of stimulation)

Each patient will be evaluated before and after stimulation by a battery of gait and movement tests using wearing sensors technology.

Sensors assessment:

The following gait parameters will be evaluated in normal and cognitive/motor dual-tasks:

i) step length ii) step variability iii) step phases iv) turning speed

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Parkinson Disease Gait Disorders, Neurologic Parkinsonism Gait, Festinating

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Each patient received both rTMS and sham cerebellar stimulation in randomized order in two different sessions, separated by at least 2 weeks. In each session, motor tasks, clinical scales and wearing sensor assessments were tested twice in all patients: at baseline (pre-stimulation) and after rTMS (post-stimulation)
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators
The patient and the examiner who administered the clinical scales were blind to the type of rTMS delivered, which was applied by another blinded experimenter.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Real Stimulation

Cerebellar Repetitive theta burst stimulation will be performed using a 3 pulses at 50-Hz repeated at a rate of 5-Hz; 20 trains of 10 bursts given with 8-s intervals for a total of 600 pulses. Intensity of rTMS was set at the 80% of Amplitude of Motor Threshold (RMT) obtained in the left motor cortex for each subject.

Group Type ACTIVE_COMPARATOR

repetitive transcranial magnetic stimulation

Intervention Type DEVICE

Cerebellar repetitive theta Burst stimulation will be performed as detailed in the Real arm description

Sham Stimulation

The rTMS coil stimulation will be applied in the same position of the real stimulation. The Stimulation will be performed like in the real arm with the difference that the coil will be masked and thus will be inactive. The patient will hear the same sound of real stimulation, which will be only functionally inactive but will be completely performed (for the whole time of duration of stimulation)

Group Type PLACEBO_COMPARATOR

repetitive transcranial magnetic stimulation

Intervention Type DEVICE

Cerebellar repetitive theta Burst stimulation will be performed as detailed in the Real arm description

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

repetitive transcranial magnetic stimulation

Cerebellar repetitive theta Burst stimulation will be performed as detailed in the Real arm description

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* established Parkinson's disease
* ability to stand alone and walk without support

Exclusion Criteria

* dementia or behavioral alterations
* contraindication to stimulation
Minimum Eligible Age

40 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Kiel

OTHER

Sponsor Role collaborator

Università degli Studi di Brescia

OTHER

Sponsor Role collaborator

Fondazione Europea di Ricerca Biomedica Ferb Onlus

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Andrea Pilotto

Parkinson's disease Rehabilitation Centre

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Andrea Pilotto, MD

Role: PRINCIPAL_INVESTIGATOR

FERB Onlus

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Parkinson's disease Rehabilitation Centre - FERB ONLUS

Trescore Balneario, , Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Andrea Pilotto, MD

Role: CONTACT

00393396245281

Cristina Rizzetti

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Andrea Pilotto, MD

Role: primary

3396245281 ext. 0039

Maria Cristina Rizzetti, MD

Role: backup

035 955326

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

19/03

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

tDCS as Treatment for Motor Function
NCT07291687 RECRUITING NA